Literature DB >> 26500982

Comparison of Effects of Different Doses Dexmedetomidine on Inhibiting Tracheal Intubation-Evoked Haemodynamic Response in the Elderly Patients.

Guan Zhan-Ying1, Wang Chang-Ming2, Tang Shuai3, Tong Lin-Lin1, Han Yu-Feng1.   

Abstract

BACKGROUND: Dexmedetomidine (DEX) is a selective α2-adrenergic receptor agonist with anxiolytic and analgesic properties. In the present study, we aimed primarily to assess the effects of DEX on sedation, cognitive function and cardiovascular reflex responses before, during and after the tracheal intubation in the elderly patients.
MATERIALS AND METHODS: Eighty patients undergoing elective abdominal surgery were randomly assigned to four Groups: Group A(saline, n=20), Group B (0.25μg/kg DEX, n=20), Group C (0.50μg/kg DEX, n=20) and Group D (1.00μg/kg DEX, n=20). With the constant speed infusion of saline and a loading different doses of DEX (diluted with saline to 50ml) for 10min respectively before induction of anaesthesia, the values of arterial pressure {systolic blood pressure (SBP), diastolic blood pressure (DBP)}, heart rate (HR) and bispectral index (BIS) at the time point of before pump DEX (T0), at the end of infusing DEX (T1), before tracheal intubation (T2), at the moment of tracheal intubation (T3) and 5min after trachea intubation (T4) were observed, oxygen saturation (SPO2) and the Modified Observers Assessment of Alertness/Sedation Scale (OAA/S) score were observed at the time of T1 and T0.
RESULTS: Comparison among Groups, compared with Group A, SBP and DBP values in Group C at T2 showed significant differences (p<0.05), SBP and DBP values in Group D at T1, T2 and T4 indicated significant differences (p<0.05), HR values in Group D at T1, T2, T3 and T4 showed significant differences (p<0.05); Compared with Group A, BIS values in Group C at T2 and T3 indicated significant differences (p<0.05), BIS values in Group D at T1, T2, T3 and T4 showed significant differences (p<0.05); Comparison between T3 andT2, means of SBP, DBP and HR in Group A and in Group B showed significant differences (p<0.05); Group D showed significant differences in SPO2 and (OAA/S) betweenT1 and T0 (p<0.05).
CONCLUSION: Comparison within Groups and between Groups in different doses DEX, the present result showed that 0.5μg/kg DEX had an effective inhibition, without respiratory depression, on tracheal intubation evoked cardiovascular response in the elderly patients.

Entities:  

Keywords:  Cardiovascular responses; Sedation

Year:  2015        PMID: 26500982      PMCID: PMC4606311          DOI: 10.7860/JCDR/2015/14624.6455

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  23 in total

1.  Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions.

Authors:  J E Hall; T D Uhrich; J A Barney; S R Arain; T J Ebert
Journal:  Anesth Analg       Date:  2000-03       Impact factor: 5.108

2.  Effect of dexmedetomidine on haemodynamic responses to laryngoscopy and intubation : perioperative haemodynamics and anaesthetic requirements.

Authors:  Munise Yildiz; Aybars Tavlan; Sema Tuncer; Ruhiye Reisli; Alper Yosunkaya; Seref Otelcioglu
Journal:  Drugs R D       Date:  2006

3.  Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist.

Authors:  R Virtanen; J M Savola; V Saano; L Nyman
Journal:  Eur J Pharmacol       Date:  1988-05-20       Impact factor: 4.432

Review 4.  Dexmedetomidine: a review of clinical applications.

Authors:  Dominic S Carollo; Bobby D Nossaman; Usha Ramadhyani
Journal:  Curr Opin Anaesthesiol       Date:  2008-08       Impact factor: 2.706

Review 5.  [Consequences and prevention methods of hemodynamic changes during laryngoscopy and intratracheal intubation].

Authors:  N Bruder; D Ortega; C Granthil
Journal:  Ann Fr Anesth Reanim       Date:  1992

6.  Dexmedetomidine and low-dose ketamine provide adequate sedation for awake fibreoptic intubation.

Authors:  Corey S Scher; Melvin C Gitlin
Journal:  Can J Anaesth       Date:  2003 Jun-Jul       Impact factor: 5.063

7.  Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate.

Authors:  J P Belleville; D S Ward; B C Bloor; M Maze
Journal:  Anesthesiology       Date:  1992-12       Impact factor: 7.892

8.  The BIS and hemodynamic changes in major burn patients according to a slow infusion of propofol for induction.

Authors:  Ji Young Bae; Do Young Choi; Chul-Ho Woo; In-Suk Kwak; Sung Ha Mun; Kwang-Min Kim
Journal:  Korean J Anesthesiol       Date:  2011-03-30

9.  Dexmedetomidine attenuates sympathoadrenal response to tracheal intubation and reduces perioperative anaesthetic requirement.

Authors:  Varshali M Keniya; Sushma Ladi; Ramesh Naphade
Journal:  Indian J Anaesth       Date:  2011-07

10.  Comparison between propofol and dexmedetomidine on depth of anesthesia: A prospective randomized trial.

Authors:  Uddalak Chattopadhyay; Suchismita Mallik; Sarmila Ghosh; Susmita Bhattacharya; Subrata Bisai; Hirak Biswas
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2014-10
View more
  4 in total

1.  Dexmedetomidine versus midazolam for sedation during endoscopy: A meta-analysis.

Authors:  Fan Zhang; Hao-Rui Sun; Ze-Bing Zheng; Ren Liao; Jin Liu
Journal:  Exp Ther Med       Date:  2016-03-24       Impact factor: 2.447

2.  Effects of preanesthetic dexmedetomidine on hemodynamic responses to endotracheal intubation in elderly patients undergoing treatment for hypertension: a randomized, double-blinded trial.

Authors:  Chan Woo Lee; Miwoon Kim
Journal:  Korean J Anesthesiol       Date:  2016-12-01

3.  Effective dose of dexmedetomidine as an adjuvant sedative to peripheral nerve blockade in elderly patients.

Authors:  C Wang; H Zhang; Q Fu
Journal:  Acta Anaesthesiol Scand       Date:  2018-02-09       Impact factor: 2.105

4.  Dexmedetomidine for the prevention of postoperative delirium in elderly patients undergoing noncardiac surgery: A meta-analysis of randomized controlled trials.

Authors:  Hai Zeng; Zunjiang Li; Jianbin He; Wenbin Fu
Journal:  PLoS One       Date:  2019-08-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.